Transcode Therapeutics Stock Minimum Initial Investment
| RNAZ Stock | USD 0.38 0.04 11.76% |
Transcode Therapeutics fundamentals help investors to digest information that contributes to Transcode Therapeutics' financial success or failures. It also enables traders to predict the movement of Transcode Stock. The fundamental analysis module provides a way to measure Transcode Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Transcode Therapeutics stock.
Transcode | Minimum Initial Investment |
Transcode Therapeutics Company Minimum Initial Investment Analysis
Transcode Therapeutics' Minimum Initial Investment refers to minimum amount the fund family or category will require an investor to deposit to acquire the very first position in the fund or to open an account. In other words, Minimum Initial Investment is a guarantee that any investment from a purchaser of a fund meets the minimum requirement of the fund.
More About Minimum Initial Investment | All Equity Analysis
Minimum Initial Investment | = | First Fund Deposit |
Transcode Minimum Initial Investment Driver Correlations
Understanding the fundamental principles of building solid financial models for Transcode Therapeutics is extremely important. It helps to project a fair market value of Transcode Stock properly, considering its historical fundamentals such as Minimum Initial Investment. Since Transcode Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Transcode Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Transcode Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Fund managers put minimum investment restrictions on fund investments in order to allow the fund to function properly. Minimum restrictions allow fund managers to regulate cash flows of the fund, while guarding it against random trades that may negatively affect fund strategy.
| Competition |
Transcode Cash And Short Term Investments
Cash And Short Term Investments |
|
Based on the recorded statements, Transcode Therapeutics has a Minimum Initial Investment of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Idea Breakdown Now
Idea BreakdownAnalyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
| All Next | Launch Module |
Transcode Fundamentals
| Return On Equity | -10.49 | ||||
| Return On Asset | -2.08 | ||||
| Current Valuation | 4.84 M | ||||
| Shares Outstanding | 17.27 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 1.99 % | ||||
| Number Of Shares Shorted | 743.58 K | ||||
| Price To Book | 3.97 X | ||||
| EBITDA | (17.97 M) | ||||
| Net Income | (18.55 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 1.04 X | ||||
| Total Debt | 450.57 K | ||||
| Current Ratio | 8.06 X | ||||
| Book Value Per Share | 2.62 X | ||||
| Cash Flow From Operations | (18.07 M) | ||||
| Short Ratio | 0.50 X | ||||
| Earnings Per Share | 168.84 X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.65 | ||||
| Market Capitalization | 6.56 M | ||||
| Total Asset | 5.17 M | ||||
| Retained Earnings | (46.42 M) | ||||
| Working Capital | 964.85 K | ||||
| Net Asset | 5.17 M |
About Transcode Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Transcode Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transcode Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transcode Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.